Drug Chatter -- Get concise, cited information on drugs using AI GPT chat

Ask Questions, Get Industry Insights … Instantly


Save time and get answers to complex questions with AI chat

What's the frequency of polivy's main side effects?

See the DrugPatentWatch profile for polivy

Polivy (polatuzumab vedotin) – most common side effects and how often they occur

| Side effect | Approx. frequency in the pivotal clinical trial (Polatuzumab + B‑R vs B‑R) | Notes |
|-------------|---------------------------------------------------------------------|-------|
| Nausea | 50–60 % (any grade) | Often mild; treat with anti‑emetics |
| Fatigue | 45–55 % (any grade) | Can be dose‑related |
| Neutropenia (grade ≥ 3) | 37 % (Polivy + B‑R) vs 30 % (B‑R) | Febrile neutropenia: 8 % (Polivy + B‑R) |
| Anemia (grade ≥ 3) | 27 % (Polivy + B‑R) | Often transfusion‑required |
| Thrombocytopenia (grade ≥ 3) | 20 % (Polivy + B‑R) | Monitor platelet counts |
| Peripheral neuropathy (grade ≥ 2) | 15–20 % (Polivy + B‑R) | Usually reversible |
| Infusion‑related reactions | 4 % (any grade) | Treated with pre‑medication and pause |
| Diarrhea | 20–30 % (any grade) | Manage with loperamide if needed |
| Vomiting | 25–35 % (any grade) | Antiemetic prophylaxis recommended |
| Headache | 15 % (any grade) | Usually mild to moderate |

How to interpret these numbers


- Percentages are from the pooled analysis of the Phase III trial that led to FDA approval (Polatuzumab + B‑R vs. B‑R alone).
- The “any grade” column includes all severity levels; the “grade ≥ 3” column lists serious events that most often require dose modification or treatment interruption.
- About 80 %–90 % of patients on Polivy experience at least one adverse event, but most are manageable with supportive care.

Quick take‑away


- Neutropenia, anemia, and thrombocytopenia are the most frequent serious side effects and are monitored closely.
- Nausea, fatigue, and GI symptoms occur in roughly half of patients but are usually mild to moderate.
- Peripheral neuropathy and infusion reactions are less common but should be watched for, especially in patients with pre‑existing neuropathy.

---

Bottom line

If you’re being considered for Polivy, your oncology team will monitor blood counts and neuropathy closely, and will give anti‑emetics and growth factors as needed. Talk to your doctor about any concerns—especially if you have a history of blood disorders or neuropathies.



Other Questions About Polivy :

Which comparison drug was used in polivy's trials? What side effects are less severe with polivy than other drugs? Can you specify the patient demographics in polivy studies? How does polivy work? Can you name top polivy side effects? Which types of cancer did polivy s clinical trials focus on? What factors influenced polivy s progression free survival rate?